SG10202105262QA - St-246 liquid formulations and methods - Google Patents

St-246 liquid formulations and methods

Info

Publication number
SG10202105262QA
SG10202105262QA SG10202105262QA SG10202105262QA SG10202105262QA SG 10202105262Q A SG10202105262Q A SG 10202105262QA SG 10202105262Q A SG10202105262Q A SG 10202105262QA SG 10202105262Q A SG10202105262Q A SG 10202105262QA SG 10202105262Q A SG10202105262Q A SG 10202105262QA
Authority
SG
Singapore
Prior art keywords
methods
liquid formulations
formulations
liquid
Prior art date
Application number
SG10202105262QA
Inventor
Shanthakumar R Tyavanagimatt
Melialani A C L Stone
William C Weimers
Gopi Krishna Kasi
Peter N K Samuel
Tove' C Bolken
Dennis E Hruby
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of SG10202105262QA publication Critical patent/SG10202105262QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24071Demonstrated in vivo effect
SG10202105262QA 2010-08-05 2011-08-02 St-246 liquid formulations and methods SG10202105262QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37097110P 2010-08-05 2010-08-05
US201161450359P 2011-03-08 2011-03-08

Publications (1)

Publication Number Publication Date
SG10202105262QA true SG10202105262QA (en) 2021-06-29

Family

ID=45559790

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202105262QA SG10202105262QA (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods
SG10201506031UA SG10201506031UA (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods
SG2013007000A SG187243A1 (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201506031UA SG10201506031UA (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods
SG2013007000A SG187243A1 (en) 2010-08-05 2011-08-02 St-246 liquid formulations and methods

Country Status (15)

Country Link
US (5) US9233097B2 (en)
EP (1) EP2600715B1 (en)
JP (1) JP5898196B2 (en)
KR (1) KR101868117B1 (en)
CN (2) CN106074370A (en)
AR (1) AR082566A1 (en)
AU (1) AU2011285871B8 (en)
BR (1) BR112013002646B1 (en)
CA (1) CA2807528C (en)
DK (1) DK2600715T3 (en)
IL (1) IL224430B (en)
MX (2) MX347795B (en)
SG (3) SG10202105262QA (en)
WO (1) WO2012018810A1 (en)
ZA (1) ZA201300930B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CN104414983B (en) * 2013-08-28 2018-09-04 山东新时代药业有限公司 A kind of injection fosaprepitant dimeglumine sterile lyophilized powder and its preparation process
JP6594303B2 (en) * 2013-11-19 2019-10-23 シガ・テクノロジーズ・インコーポレーテッド Rehydration of micronized Tecobilimat monohydrate
JP6632999B2 (en) * 2014-06-12 2020-01-22 ユニバーシティ オブ ノートルダム デュ ラック Compositions and methods for treating neurological diseases and cerebral injury
US10488733B2 (en) 2015-04-10 2019-11-26 Bae Systems Plc Long range electromagnetic radiation sensor having a control system to heat and/or ionize the air within three-dimensional portions of an atmospheric volume
CN107625967B (en) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 Tecoviri injection pharmaceutical composition and preparation method thereof
CN107638571B (en) * 2016-07-15 2021-07-06 中国人民解放军军事医学科学院毒物药物研究所 Tecoviri oral pharmaceutical composition and preparation method thereof
CN106407676A (en) * 2016-09-12 2017-02-15 广东省农业科学院动物科学研究所 Monte Carlo simulation based drug effect calculating method for antibacterial drug
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US20230082992A1 (en) * 2021-09-11 2023-03-16 Viron Therapeutics LLC Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
US11903962B1 (en) 2023-05-07 2024-02-20 Michael Farber Isoxazoline complexes and compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220294A1 (en) 2002-03-21 2003-11-27 Wallace Kendall B. Cyclodextrin compositions and methods of treating viral infections
ES2632313T3 (en) * 2003-06-20 2017-09-12 Siga Technologies Inc. Compounds, compositions and methods for the treatment and prevention of orthopoxvirus infections and associated diseases
WO2006067584A1 (en) * 2004-12-23 2006-06-29 Pfizer Limited 8-aza-bicyclo (3.2.1) octane derivatives with an activity on chemokine ccr5 receptors
JP2008535862A (en) * 2005-04-08 2008-09-04 キメリクス,インコーポレイテッド Compounds, compositions and methods for the treatment of poxvirus infections
PL2335707T3 (en) * 2005-10-26 2015-10-30 Cydex Pharmaceuticals Inc Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20100056500A1 (en) 2006-11-21 2010-03-04 Thitiwan Buranachokaisan Stable Parenteral Formulation
JP2010535705A (en) 2007-04-23 2010-11-25 シガ テクノロジーズ,インコーポレーテッド Chemicals, compositions and methods for the treatment and prevention of orthopoxvirus infection and related diseases
PT2313111E (en) * 2008-08-01 2013-12-05 Ventirx Pharmaceuticals Inc Toll-like receptor agonist formulations and their use

Also Published As

Publication number Publication date
AU2011285871A1 (en) 2013-02-21
MX2013001389A (en) 2013-06-07
US9907859B2 (en) 2018-03-06
US9233097B2 (en) 2016-01-12
BR112013002646A2 (en) 2013-02-04
US20160082128A1 (en) 2016-03-24
AU2011285871B2 (en) 2015-04-23
MX368106B (en) 2019-09-19
US20200138974A1 (en) 2020-05-07
US20140011854A1 (en) 2014-01-09
JP2013532729A (en) 2013-08-19
CN103281898A (en) 2013-09-04
US20180185514A1 (en) 2018-07-05
JP5898196B2 (en) 2016-04-13
AU2011285871B8 (en) 2015-05-14
US10124071B2 (en) 2018-11-13
CA2807528A1 (en) 2012-02-09
CN106074370A (en) 2016-11-09
US20190038767A1 (en) 2019-02-07
US10864282B2 (en) 2020-12-15
DK2600715T3 (en) 2020-03-16
IL224430B (en) 2019-09-26
SG187243A1 (en) 2013-02-28
US10576165B2 (en) 2020-03-03
SG10201506031UA (en) 2015-09-29
AR082566A1 (en) 2012-12-19
KR20130135836A (en) 2013-12-11
CA2807528C (en) 2018-09-25
EP2600715A1 (en) 2013-06-12
MX347795B (en) 2017-05-12
BR112013002646B1 (en) 2022-01-04
WO2012018810A9 (en) 2012-04-05
KR101868117B1 (en) 2018-06-18
EP2600715B1 (en) 2019-12-11
EP2600715A4 (en) 2016-04-20
WO2012018810A1 (en) 2012-02-09
AU2011285871A8 (en) 2015-05-14
ZA201300930B (en) 2015-11-25

Similar Documents

Publication Publication Date Title
HUS2100032I1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
HK1187049A1 (en) Bisaryl-bonded aryltriazolones and use thereof
ZA201300930B (en) St-246 liquid formulations and methods
GB2481881B (en) Liquid formulations
ZA201208173B (en) Peptices and their use
PT3650125T (en) Liquid atomizer and methods
PT2605757E (en) Nalbuphine-based formulations and uses thereof
EP2558137A4 (en) Methods and combination
HK1188984A1 (en) Methods and devices for using isoperillyl alcohol
PL2521445T3 (en) Formulation and use thereof
EP2594246A4 (en) Liquid cosmetic
HK1201451A1 (en) Compositions and methods
GB201018650D0 (en) Methods and compositions
EP2533762A4 (en) Retinol formulations and methods for their use
GB201008286D0 (en) Device and use
GB201013871D0 (en) Liquid formulations
GB201008873D0 (en) Liquid formulations
EP2638160A4 (en) Nuclions and ribocapsids
GB201018651D0 (en) Methods and compositions
GB201010083D0 (en) Compositions and methods
GB201009767D0 (en) Compositions and methods
TWM385891U (en) Thermo-pressing and thermo-cutting device
GB201001384D0 (en) Light-fitting and associated methods
GB201113314D0 (en) Formulations and processes
GB201003741D0 (en) Methods and therapeutic compositions